The Experts below are selected from a list of 13899 Experts worldwide ranked by ideXlab platform

David A Decker - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic Estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective Estrogen Receptor Modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with Estrogen Receptor positive breast cancer (n=24) using an AI or SERM and vaginal Estrogens (VE) to control atrophic vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.

S M Wills - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic Estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective Estrogen Receptor Modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with Estrogen Receptor positive breast cancer (n=24) using an AI or SERM and vaginal Estrogens (VE) to control atrophic vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.

Mitch Dowsett - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic Estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective Estrogen Receptor Modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with Estrogen Receptor positive breast cancer (n=24) using an AI or SERM and vaginal Estrogens (VE) to control atrophic vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.

Daniel F Hayes - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic Estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective Estrogen Receptor Modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with Estrogen Receptor positive breast cancer (n=24) using an AI or SERM and vaginal Estrogens (VE) to control atrophic vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.

Elizabeth Folkerd - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic Estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with Estrogen Receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective Estrogen Receptor Modulator (SERM) and VE for 90 days for atrophic vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal Estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective Estrogen Receptor Modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic Estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective Estrogen Receptor Modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with Estrogen Receptor positive breast cancer (n=24) using an AI or SERM and vaginal Estrogens (VE) to control atrophic vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.